Diphencyprone - Phio Pharmaceuticals
Alternative Names: Diphenylcyclopropenone; SamcyproneLatest Information Update: 03 Oct 2024
At a glance
- Originator Hapten Pharmaceuticals
- Developer Hapten Pharmaceuticals; Phio Pharmaceuticals
- Class Antineoplastics; Antivirals; Cyclopropanes; Haptens; Skin disorder therapies; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alopecia areata; Cancer metastases; Warts
Highest Development Phases
- Phase III Alopecia areata
- Phase II Cancer metastases; Warts
Most Recent Events
- 01 Sep 2024 University of Minnesota completes a phase III trial in Alopecia areata in USA (Topical) (NCT03651752)
- 01 Apr 2024 Phase-III clinical trials in Alopecia areata in USA (Topical) (NCT03651752)
- 19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals